Muro K, et al. - Exploratory subgroup analyses were described to evaluate the efficacy and safety of ramucirumab in REGARD and RAINBOW in young (≤45 and <65 years) and elderly (≥65, ≥70 and ≥75 years) patients. Ramucirumab conferred improvements in efficacy across age groups with a tolerable safety profile than the placebo. Irrespective of age, these exploratory analyses supported the use of ramucirumab in advanced gastric cancer, despite some limitations.